{"doi":"10.1016/j.tranon.2020.100917","title":"Cross-resistance of cisplatin selected cells to anti-microtubule agents: Role of general survival mechanisms","abstract":"Although the first line of therapy for epithelial ovarian cancer typically consists of taxane-platinum combination therapy, many patients develop a platinum-resistant tumor within a year. Several previous studies have looked at this cross-resistance between cisplatin and anti-microtubule drugs, but their findings have been somewhat conflicting. Here, we developed cisplatin-resistant cell lines that are resistant to low and high levels of cisplatin and explored the effects of three anti-microtubule drugs (paclitaxel, vincristine, and colchicine) on the parental and cisplatin-resistant cells. We found that cells resistant to lower levels of cisplatin were no more resistant to anti-microtubule drugs than parental cells, while cells that were resistant to higher levels of cisplatin had a subpopulation of cells that were cross-resistant to anti-microtubule drugs, clarifying discrepancies within the field. We then isolated this subpopulation by applying selective pressure with anti-microtubule drugs and performed RNA sequencing and gene set enrichment analysis to identify resistance mechanisms. This subpopulation was found to express increased levels of pro-survival TNF/NFκB signaling, among other enriched pathways, suggesting that cross-resistance was due to more general survival mechanisms found in the cisplatin-selected cells.","journal":"Translational Oncology","year":2020,"id":71775,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":17,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9447,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":309023,"name":"Skyler A. Kuhn","orcid":"0000-0003-0606-2125","position":1,"is_corresponding":false},{"id":378981,"name":"Da Yin","orcid":"0000-0002-5336-2772","position":2,"is_corresponding":false},{"id":379951,"name":"Jordan M. Hotz","orcid":null,"position":3,"is_corresponding":false},{"id":379952,"name":"Frances A. Maher","orcid":null,"position":4,"is_corresponding":false},{"id":378982,"name":"Robert W. Robey","orcid":"0000-0002-0857-3650","position":5,"is_corresponding":false},{"id":378983,"name":"Michael M. Gottesman","orcid":"0000-0001-8908-2097","position":6,"is_corresponding":false},{"id":378984,"name":"Sachi Horibata","orcid":"0000-0002-2629-7821","position":7,"is_corresponding":false},{"id":378980,"name":"Ruchi P. Patel","orcid":"0000-0001-8366-1928","position":0,"is_corresponding":true}],"reference_count":48,"raw_metadata":null,"created_at":"2026-07-18T21:44:25.469842Z","pmid":"33129114","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}